Alzheimer’s disease and Parkinson’s disease are both progressive brain diseases, but they attack different parts of the brain, produce different primary symptoms, and are treated with entirely different medications. Alzheimer’s starts with memory loss and cognitive decline. Parkinson’s starts with movement problems like tremor, stiffness, and slowness. The overlap between them, especially in later stages, is what makes the distinction confusing.
What Happens in the Brain
The two diseases are driven by different toxic proteins that accumulate in different brain regions. In Alzheimer’s, sticky clumps of a protein called beta-amyloid form plaques between brain cells, while another protein called tau tangles up inside neurons. This damage concentrates in the hippocampus and cortex, the areas responsible for memory and higher thinking. In Parkinson’s, a different protein called alpha-synuclein misfolds and clumps into structures called Lewy bodies, which damage neurons in deeper brain regions involved in movement control.
These aren’t always neatly separated. The most common subtype of Alzheimer’s, called the Lewy body variant, also shows alpha-synuclein deposits. And many people with Parkinson’s eventually develop tau and amyloid pathology. This molecular overlap helps explain why, as both diseases progress, their symptoms can start to resemble each other.
How the Symptoms Differ
The clearest difference is what shows up first. Alzheimer’s begins with gradual memory loss and difficulty with everyday cognitive tasks: forgetting recent conversations, misplacing things, struggling to follow plans or manage finances. Diagnosis requires a progressive decline in memory plus at least one other area of thinking or daily function.
Parkinson’s announces itself through the body. The hallmark symptoms are a resting tremor (often starting in one hand), stiffness in the limbs and trunk, and bradykinesia, which is a general slowness of movement. Walking becomes shuffling, facial expressions flatten, and fine motor tasks like buttoning a shirt get harder. Cognitive changes can be present early on, but they’re typically mild at first.
Different Types of Cognitive Decline
Even when both diseases cause dementia, the thinking problems feel different. In Alzheimer’s, the core deficit is in storing new memories. People genuinely lose the information. They can’t recall what happened an hour ago because the memory was never properly encoded. Broader knowledge and word-finding also deteriorate as the disease progresses.
In Parkinson’s, the cognitive profile leans more toward executive dysfunction: difficulty planning, switching between tasks, solving problems, and processing information quickly. Memory problems do occur, but they tend to involve trouble retrieving information rather than storing it. A person with Parkinson’s dementia might recall a detail with the right cue, while a person with Alzheimer’s often cannot, even with help. Research comparing the two conditions at similar levels of overall dementia severity found that Alzheimer’s patients were relatively more impaired on memory tasks, while Parkinson’s patients struggled more with executive function. The differences are relative rather than absolute, but they’re consistent enough to be clinically useful.
When Parkinson’s Leads to Dementia
Not everyone with Parkinson’s develops dementia, but a significant number do. Roughly 10% to 20% of people with Parkinson’s experience mild cognitive impairment over the course of the disease. The risk of full dementia climbs steeply with age and disease duration: it affects 16% to 20% of people aged 60 to 75 who have had Parkinson’s for five to ten years, 20% to 30% of the same age group after ten to fifteen years, and 50% to 60% of people over 75 who have had Parkinson’s for more than fifteen years.
Timing matters for the diagnosis. If dementia develops at least one year after Parkinson’s movement symptoms began, it’s classified as Parkinson’s disease dementia. If cognitive decline appears before, alongside, or within one year of movement symptoms, the diagnosis shifts to Lewy body dementia. The distinction matters because the two conditions, while related, can follow different trajectories and respond differently to treatment.
Who Gets Each Disease
Alzheimer’s is far more common. An estimated 6.9 million Americans age 65 and older are living with Alzheimer’s dementia, roughly 1 in 9 people in that age group. The risk rises sharply with age: 5% of people aged 65 to 74, 13.2% of those 75 to 84, and a full third of people 85 and older. Globally, more than 55 million people are living with dementia of all types, and Alzheimer’s accounts for the majority of those cases.
Parkinson’s is less prevalent, though still one of the most common neurodegenerative diseases worldwide. It tends to appear slightly earlier, with the average age of diagnosis in the early 60s compared to Alzheimer’s, which more commonly surfaces in the mid-to-late 60s or 70s. Parkinson’s also accounts for about 3.6% of all dementia cases.
Genetic Risk Factors
The genetic landscapes of the two diseases overlap somewhat but involve different key players. For Alzheimer’s, the strongest known genetic risk factor is a variant of the APOE gene called E4. Carrying one copy roughly triples your risk; carrying two copies increases it tenfold or more.
For Parkinson’s, the most important genetic contributors are variants in two genes: GBA1, which is involved in about 10% of Parkinson’s cases, and LRRK2, found in about 2%. GBA1 encodes an enzyme that helps cells break down waste, while LRRK2 produces a signaling protein. Mutations in either can disrupt normal cell cleanup processes, allowing toxic proteins to accumulate. Interestingly, the APOE E4 variant linked to Alzheimer’s also appears to increase the risk of dementia in people who already have Parkinson’s, reinforcing the biological connection between the two diseases. Beyond these individual genes, both conditions are influenced by hundreds of smaller genetic variations that collectively raise or lower risk.
How Each Disease Is Diagnosed
Alzheimer’s diagnosis has moved increasingly toward biological markers. Updated 2024 criteria from the Alzheimer’s Association define the disease as a biological process that begins before symptoms appear, detectable through biomarkers. The most informative tests include amyloid PET brain scans, which reveal protein plaques, and blood or spinal fluid tests measuring a specific form of the tau protein called phosphorylated tau 217. These tools can now identify Alzheimer’s pathology years before significant memory loss.
Parkinson’s diagnosis still relies heavily on clinical evaluation of movement symptoms, though imaging is increasingly helpful. A DaTscan uses a radioactive tracer to visualize dopamine-producing nerve cells in the brain; reduced activity supports a Parkinson’s diagnosis. Research from the NIH has also shown that PET scans of the heart, measuring levels of the chemical messenger norepinephrine, can predict who will develop Parkinson’s or Lewy body dementia. People at risk who showed low cardiac radioactivity on these scans were highly likely to be diagnosed during follow-up.
Treatment Approaches
The medications for each disease target completely different brain chemistry. Alzheimer’s treatments focus on boosting a chemical messenger called acetylcholine, which is depleted as the disease destroys neurons in thinking and memory circuits. Drugs in this class work by blocking the enzyme that breaks down acetylcholine, effectively keeping more of it available in the brain. These medications can produce meaningful improvements in cognition, daily functioning, and behavioral symptoms, though they don’t stop the underlying disease.
Parkinson’s treatment centers on restoring dopamine, the chemical messenger that controls smooth, coordinated movement. The standard approach uses a precursor molecule that the brain converts into dopamine, combined with a second compound that prevents the precursor from being broken down before it reaches the brain. This combination remains the most effective treatment for Parkinson’s motor symptoms. It can also be paired with other drugs that reduce tremor through different pathways.
The challenge arises when conditions overlap. Someone with Parkinson’s disease dementia may benefit from both types of medication, but the drugs can work against each other. Boosting acetylcholine to help cognition can worsen movement symptoms, and boosting dopamine for movement can sometimes trigger hallucinations or confusion. Managing both requires careful balancing.
Life Expectancy and Progression
Both diseases shorten life, but their timelines differ. For Parkinson’s, population-based studies estimate an average survival of about 9.6 years from diagnosis, assuming a typical diagnosis age in the early 70s. Cognitive impairment at the time of diagnosis significantly worsens the outlook, dropping expected survival to around 8.2 years compared to 11.6 years for those without early cognitive changes. Pneumonia is the most common identified cause of death.
Alzheimer’s survival from diagnosis typically ranges from 4 to 8 years, though some people live considerably longer. The disease tends to progress through predictable stages, from mild forgetfulness to complete dependence on caregivers, with the later stages often lasting years. Because Alzheimer’s is diagnosed later in life on average and progresses more relentlessly through cognitive function, the overall survival window is generally shorter than Parkinson’s, though individual variation is enormous in both conditions.